BRAF and melanoma: In fact, this has been elegantly demonstrated accidentally in patients receiving the Braf inhibitor vemurafenib, which inhibits p42/44 MAPK signaling in melanoma, but can provoke squamous cell carcinoma, which has p53 mutations.14 The major discovered differences between these tumors have increased and are summarized in Table 1.